FDA Grants Priority Review to Liso-cel for Relapsed or Refractory Large B-Cell Lymphoma

Bristol-Meyers Squibb Company announced that the FDA granted a priority review to its BLA for liso-cel to treat patients with relapsed or refractory large B-cell lymphoma.

Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news